^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    CancerVision

    Company:
    Inocras
    Type:
    Laboratory Developed Test
    Details
    Evidence

    News

    1m
    Inocras pioneers precision health with revolutionary whole genome insights (Businesswire)
    "Inocras...proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively."
    Launch
    |
    CancerVision
    1m
    Advancing cancer MRD monitoring through tumor whole-genome informed, duplex ctDNA sequencing. (ASCO 2024)
    Our integration of tumor-WGS-informed duplex cfDNA sequencing methods significantly enhances the sensitivity of sequencing-based MRD assays, achieving a technical LoD limit of 10-7 for detecting ctDNA in cancer patients. These approaches represent a breakthrough in monitoring MRD in real-world cancer patients.
    Circulating tumor DNA
    |
    MSI (Microsatellite instability)
    |
    CancerVision
    1year
    Genome Insight launches in the U.S. with innovative whole genome sequencing approach that offers unprecedented, actionable insights in cancer care (PRNewswire)
    "Genome Insight...announced today the U.S. launch of CancerVision, their innovative whole genome sequencing (WGS) test designed to provide accurate, timely and medically meaningful insights that collectively guide personalized healthcare decisions."
    Launch US
    |
    CancerVision